How to Build a Culture of Quality in Pharma & Biotech

Introduction

In the world of pharma and biotech, everyone agrees that quality matters. Companies spend millions on training, audits, and quality systems, but somehow, the same problems keep coming back. From repeat CAPAs to audit observations that echo the last inspection, it’s clear that something deeper is at play. The truth? It’s not just about having quality processes in place, it’s about how those processes are lived every day

Building a true pharma quality culture means shifting mindsets, not just upgrading systems. And that shift starts with understanding that quality isn’t just a department. It’s a shared responsibility that must show up in daily behaviours, cross-functional interactions, and even in how failures are handled. Culture can’t be mandated from the top, it must be reinforced in the middle.

Why SOPs Don’t Equal Accountability

Every organisation has SOPs, work instructions, and mandatory training. Yet, even with all these controls, teams treat compliance as a checkbox. Following the steps isn’t the same as owning the outcome. And that’s the gap many companies miss.

For example, when a deviation occurs, the investigation may be compliant, but the corrective action is mechanical. Without understanding why the deviation happened or what mindset led to it, the organisation is only treating the symptom.

In recent years, the FDA’s top 10 Form 483 observations have remained remarkably consistent, with issues around documentation, deviation investigation, and written procedures appearing unchanged for over 23 years. This striking stagnation reveals a deeper cultural issue: audit findings aren’t just one-offs, they’re repeat observations that persist because root causes aren’t truly addressed.

Simply having rules and SOPs in place isn’t enough. What’s needed is ownership, clarity, and behavioral change, the foundational elements of any enduring compliance culture.

Spotting Cultural Weakness Before It Shows Up in an Audit

Culture isn’t measured in dashboards. It’s reflected in how teams behave under pressure. You can spot early signs of breakdown long before an audit:

• Passive or last-minute audit preparation
• Repeated CAPAs for the same issues across different sites
• Quality being discussed only during crises
• Training that is completed but not internalised.

The Silo Problem: When Quality Lives in One Department

Too often, quality is owned by a single function. Manufacturing has its KPIs. R&D is chasing timelines. Regulatory is managing submissions. But quality, if it’s to be effective, must connect all of them.

Siloed systems and disconnected data lead to:

• Training not being tied to recent deviations
• Audit findings not flowing into operational practices
• Suppliers being qualified without input from the shop floor

In quality in biotech, where innovation cycles are shorter and teams more distributed, this misalignment becomes a bigger risk. When functions don’t share context, the organisation responds slowly, if at all.

The Visibility Gap That Keeps Leaders in the Dark

Leaders believe things are under control because reports are green. But that’s the danger of fragmented systems. A CAPA may be closed in the QMS, but the root cause may still be active in a supplier process or training gap.

Real quality culture needs real visibility. Not just static dashboards, but real-time insights into:

• Training effectiveness
• Supplier performance trends
• CAPA ageing and recurrence
• Site-specific risk profiles

When Quality Is Routine, Not Reactive

Culture doesn’t change overnight. But it does shift when quality becomes part of the everyday conversation, not just a checklist before inspections. That means:

• Including quality metrics in business reviews
• Discussing quality outcomes in product and sourcing meetings
• Encouraging quality observations from frontline staff, not just auditors

In biotech environments, where speed trumps structure, embedding quality into early R&D discussions can prevent scale-up headaches later.

Conclusion

You can’t train your way into culture. You have to build it, day by day, decision by decision, system by system. In the high-stakes world of pharma and quality in biotech, that means closing the gaps between policy and practice, between intent and action.

When people are connected through shared data, integrated workflows, and visible outcomes, accountability isn’t enforced. It’s assumed.

Quality culture doesn’t just show up in inspections, it should shape decisions in procurement, training, supplier selection, and even hiring. Cross-functional huddles where quality concerns are openly discussed uncover risks early, turning informal discussions into powerful feedback loops. Encouraging a speak-up culture is critical. When frontline employees feel safe to raise quality concerns without fear of blame, systemic improvement becomes possible.

In biotech startups, quality plays catch-up to product innovation. But proactive cultural investment in early-stage operations can prevent costly regulatory setbacks later. Metrics alone can’t capture culture. But consistent behaviour across teams, like timely CAPA closure, thorough root cause analysis, and transparent deviation logging, signal a maturing mindset.

Frequently Asked Questions (FAQs)

• When regulatory bodies look at culture, what are they observing?

  FDA inspectors increasingly scrutinize quality culture during inspections. They may check if senior leadership signs off on product reviews, link CAPA effectiveness to root cause closure per FDA’s voluntary Quality Metrics guidance, or see if employees speak openly about quality issues rather than hiding them, indicators now considered in risk-based inspection selection processes.

• How do we ensure CAPAs truly address root causes, not just symptoms?

  A strong cultural shift means CAPAs become a learning tool, not a tick-box exercise. Evaluate whether investigations dig into system-wide or training gaps, not just procedural compliance. Use audits to track if the same issues keep resurfacing at different locations; persistent patterns indicate CAPAs aren't addressing deeper causes.

• Can supplier training and quality be part of our culture shift?

  Absolutely. For pharma quality culture to scale, supplier partners must adopt consistent standards. Include supplier training alert timelines in your QMS, and track supplier-driven deviations. Connect feedback loops so supplier corrective actions are visible to internal teams. This shared responsibility builds external accountability and deepens the quality mindset beyond your walls.